Martin Burstein Sells 28,988 Shares of RA Medical Systems Inc (NYSE:RMED) Stock
RA Medical Systems Inc (NYSE:RMED) major shareholder Martin Burstein sold 28,988 shares of RA Medical Systems stock in a transaction that occurred on Monday, December 9th. The stock was sold at an average price of $1.06, for a total transaction of $30,727.28. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.
Martin Burstein also recently made the following trade(s):
- On Friday, December 6th, Martin Burstein sold 1,208 shares of RA Medical Systems stock. The stock was sold at an average price of $1.27, for a total transaction of $1,534.16.
RMED opened at $0.90 on Friday. The business’s 50-day moving average price is $1.41 and its 200-day moving average price is $2.16. The company has a current ratio of 5.69, a quick ratio of 5.37 and a debt-to-equity ratio of 0.07. RA Medical Systems Inc has a 12 month low of $0.85 and a 12 month high of $10.19.
A number of institutional investors have recently made changes to their positions in the business. Bourne Lent Asset Management Inc. purchased a new position in RA Medical Systems in the 3rd quarter worth approximately $70,000. FNY Investment Advisers LLC purchased a new stake in shares of RA Medical Systems during the third quarter valued at approximately $58,000. BlackRock Inc. boosted its stake in shares of RA Medical Systems by 94.2% during the second quarter. BlackRock Inc. now owns 22,438 shares of the company’s stock valued at $81,000 after purchasing an additional 10,883 shares during the period. Weil Company Inc. bought a new position in shares of RA Medical Systems in the second quarter worth approximately $63,000. Finally, Envestnet Asset Management Inc. bought a new position in shares of RA Medical Systems in the second quarter worth approximately $45,000. 17.48% of the stock is currently owned by institutional investors and hedge funds.
A number of equities research analysts have recently issued reports on the stock. Maxim Group reaffirmed a “buy” rating and issued a $3.00 price objective on shares of RA Medical Systems in a research note on Friday, December 6th. Zacks Investment Research cut shares of RA Medical Systems from a “hold” rating to a “sell” rating in a research report on Thursday, December 5th. One analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $4.13.
RA Medical Systems Company Profile
Ra Medical Systems, Inc, a commercial-stage medical device company, develops, manufactures, and markets excimer lasers for use in the treatment of vascular and dermatological diseases. The company offers DABRA (destruction of arteriosclerotic blockages by laser radiation ablation), a minimally-invasive excimer laser and disposable catheter system that is used by physicians in the endovascular treatment of vascular blockages resulting from lower extremity vascular disease.
Featured Article: What is the Federal Reserve?
Receive News & Ratings for RA Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RA Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.